Pharmacogenetic research in Kazakhstan

Area of Science:

• Pharmacogenomics and Biotechnology
• Genetics and Pharmacology
• Personalized Medicine

Background:

• Pharmacogenomic research in Kazakhstan is a developing field with significant recent advancements.
• The National Scientific Laboratory for Biotechnology is actively pursuing government-funded projects.
• Research focuses on identifying genetic markers for drug susceptibility and pharmacogenomic markers for cardiovascular diseases in the Kazakh population.

Purpose of the Study:

• To identify genetic markers influencing drug response in the Kazakh population.
• To determine pharmacogenomic markers for cardiovascular diseases.
• To develop personalized drug dosage regimens, exemplified by Warfarin.

Main Methods:

• Real-time PCR and direct DNA sequencing were employed for pharmacogenomic studies.
• DNA was isolated from patient venous blood or buccal cells.
• Allelic frequencies of key polymorphisms were calculated for the Kazakh population.

Main Results:

• Key polymorphisms (CYP2C9, CYP2C19, CYP3A4, VKORC1, etc.) in the Kazakh population have had their allelic frequencies determined.
• A unique repository of DNA samples has been established.
• A patent for Warfarin genotyping in the Kazakh population has been secured, with another patent application for an express method of Warfarin dosing correction positively evaluated.

Conclusions:

• Pharmacogenomic studies in Kazakhstan are yielding promising results for personalized medicine.
• The identified genetic markers and developed testing kits will facilitate rational drug selection and dosage.
• These advancements aim to optimize therapeutic outcomes for the Kazakh population.